OTLK · Outlook Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Ghiath M. Sukhtian Director | ▲ Buy | Open Market | 24,617,320 Shares held | 8/12/2026 | View profile |
| BioLexis Pte Ltd. 10% Owner | ▼ Sell | Other | 22,982,529 Shares held | 4/21/2022 | View profile |
| Pillai Arun Kumar Director | ▼ Sell | Other | 22,982,529 Shares held | 2/1/2022 | View profile |
| Syntone Ventures LLC | ▲ Buy | Open Market | 1,705,438 Shares held | 4/15/2024 | View profile |
| Jeff Evanson Chief Commercial Officer | ▲ Buy | Open Market | 808,459 Shares held | 3/7/2024 | View profile |
| Dagnon Terry Chief Operating Officer | ▼ Sell | Open Market | 653,058 Shares held | 4/20/2023 | View profile |
| Kurt J. Hilzinger Director | ▲ Buy | Open Market | 423,655 Shares held | 5/26/2026 | View profile |
| Faisal Ghiath Sukhtian Director | ▲ Buy | Open Market | 220,972 Shares held | 7/29/2026 | View profile |
| Robert Charles Jahr Chief Executive Officer | ▲ Buy | Open Market | 151,515 Shares held | 8/14/2026 | View profile |
| Lawrence A. Kenyon Chief Financial Officer | ▲ Buy | Open Market | 106,956 Shares held | 8/14/2026 | View profile |
| Yezan Munther Haddadin Director | ▲ Buy | Open Market | 66,167 Shares held | 6/2/2026 | View profile |
| TRENARY C RUSSELL III CEO and President | ▲ Buy | Open Market | 54,925 Shares held | 6/21/2022 | View profile |
| Randy H. Thurman Director | ▲ Buy | Open Market | 5,593 Shares held | 5/26/2026 | View profile |
Transaction History
| Lawrence A. Kenyon | ▲ Buy | Open Market | 101,010 | — | 8/14/2026 |
| Robert Charles Jahr | ▲ Buy | Open Market | 151,515 | — | 8/14/2026 |
| Ghiath M. Sukhtian | ▲ Buy | Open Market | 2,525,252 | $2.5M | 8/12/2026 |
| Faisal Ghiath Sukhtian | ▲ Buy | Open Market | 95,398 | $100K | 7/29/2026 |
| Yezan Munther Haddadin | ▲ Buy | Open Market | 29,000 | $24K | 6/2/2026 |
| Ghiath M. Sukhtian | ▲ Buy | Open Market | 8,539,709 | $5.0M | 5/28/2026 |
| Faisal Ghiath Sukhtian | ▲ Buy | Open Market | 122,174 | $50K | 5/27/2026 |
| Kurt J. Hilzinger | ▲ Buy | Open Market | 400,000 | $177K | 5/26/2026 |
| Randy H. Thurman | ▲ Buy | Open Market | 5,000 | $2K | 5/26/2026 |
| Yezan Munther Haddadin | ▲ Buy | Open Market | 34,000 | $15K | 5/26/2026 |
| Ghiath M. Sukhtian | ▲ Buy | Grant | 4,285,714 | $6.0M | 5/27/2025 |
| Lawrence A. Kenyon | ▲ Buy | Open Market | 5,000 | $28K | 9/26/2024 |
| Syntone Ventures LLC | ▲ Buy | Open Market | 714,286 | — | 4/15/2024 |
| Yezan Munther Haddadin | ▲ Buy | Open Market | 1,882 | $22K | 3/28/2024 |
| Ghiath M. Sukhtian | ▲ Buy | Grant | 2,305,714 | — | 3/18/2024 |
| Jeff Evanson | ▲ Buy | Open Market | 62,484 | $26K | 3/7/2024 |
| Dagnon Terry | ▼ Sell | Open Market | 520,000 | $590K | 4/20/2023 |
| Jeff Evanson | ▼ Sell | Open Market | 267,000 | $296K | 1/20/2023 |
| Jeff Evanson | ▼ Sell | Open Market | 103,255 | $126K | 1/19/2023 |
| Jeff Evanson | ▼ Sell | Open Market | 33,738 | $42K | 1/18/2023 |
| Jeff Evanson | ▼ Sell | Open Market | 27,162 | $36K | 1/17/2023 |
| Ghiath M. Sukhtian | ▲ Buy | Grant | 14,230,418 | $12.5M | 12/28/2022 |
| Faisal Ghiath Sukhtian | ▲ Buy | Open Market | 30,000 | $39K | 10/7/2022 |
| Yezan Munther Haddadin | ▲ Buy | Open Market | 3,600 | $5K | 10/7/2022 |
| Yezan Munther Haddadin | ▲ Buy | Open Market | 29,743 | $38K | 10/6/2022 |
| Kurt J. Hilzinger | ▲ Buy | Open Market | 15,662 | $19K | 10/5/2022 |
| Kurt J. Hilzinger | ▲ Buy | Open Market | 95,541 | $123K | 10/4/2022 |
| Kurt J. Hilzinger | ▲ Buy | Open Market | 41,798 | $52K | 10/3/2022 |
| Kurt J. Hilzinger | ▲ Buy | Open Market | 33,199 | $42K | 9/30/2022 |
| Kurt J. Hilzinger | ▲ Buy | Open Market | 13,800 | $16K | 9/29/2022 |
| TRENARY C RUSSELL III | ▲ Buy | Open Market | 19,925 | $21K | 6/21/2022 |
| Dagnon Terry | ▲ Buy | Open Market | 10,000 | $11K | 6/21/2022 |
| Faisal Ghiath Sukhtian | ▼ Sell | Other | 27,982,529 | — | 4/21/2022 |
| BioLexis Pte Ltd. | ▼ Sell | Other | 27,982,529 | — | 4/21/2022 |
| Kurt J. Hilzinger | ▲ Buy | Open Market | 27,708 | $47K | 3/1/2022 |
| Kurt J. Hilzinger | ▲ Buy | Open Market | 6,000 | $10K | 2/28/2022 |
| Kurt J. Hilzinger | ▲ Buy | Open Market | 41,160 | $60K | 2/24/2022 |
| Kurt J. Hilzinger | ▲ Buy | Open Market | 79,535 | $115K | 2/23/2022 |
| Kurt J. Hilzinger | ▲ Buy | Open Market | 95,597 | $142K | 2/22/2022 |
| Pillai Arun Kumar | ▼ Sell | Other | 2,500,000 | $3.1M | 2/1/2022 |
| Ghiath M. Sukhtian | ▼ Sell | Other | 2,500,000 | $3.1M | 2/1/2022 |
| TRENARY C RUSSELL III | ▲ Buy | Open Market | 25,000 | $35K | 12/6/2021 |
| Dagnon Terry | ▲ Buy | Open Market | 25,201 | $35K | 12/6/2021 |
| Jeff Evanson | ▲ Buy | Open Market | 35,200 | $47K | 12/3/2021 |
| Dagnon Terry | ▲ Buy | Open Market | 10,000 | $14K | 12/3/2021 |
| Yezan Munther Haddadin | ▲ Buy | Open Market | 10,000 | $14K | 12/2/2021 |
| Faisal Ghiath Sukhtian | ▲ Buy | Open Market | 18,000 | $25K | 12/2/2021 |
| TRENARY C RUSSELL III | ▲ Buy | Open Market | 10,000 | $14K | 12/2/2021 |
| Ghiath M. Sukhtian | ▲ Buy | Open Market | 16,000,000 | $20.0M | 11/29/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Kodiak Sciences stock rises on trial success
Kodiak Sciences shares surged 70% after its eye-disease drugs passed a key clinical trial. This news is specific to Kodiak Sciences and does not directly involve Outlook Therapeutics. The provided data contains no recent news or developments regarding OTLK, so this entry reflects the absence of company-specific updates.
Kodiak Sciences stock rises on trial success. Kodiak Sciences shares surged 70% after its eye-disease drugs passed a key clinical trial. This news is specific to Kodiak Sciences and does not directly involve Outlook Therapeutics. The provided data contains no recent news or developments regarding OTLK, so this entry reflects the absence of company-specific updates.